Replies to post #11650 on DNAprint Genomics (DNAG)

[Bill H]

(PR NEWSWIRE) DNAPrint(TM) Launches ANCESTRYbyDNA(TM) 2.5, The Most Powerful BG
Admixture Test Ever Developed
DNAPrint(TM) Launches ANCESTRYbyDNA(TM) 2.5, The Most Powerful BGA Admixture Tes
Ever Developed

SARASOTA, Fla., Jan. 27 /PRNewswire/ -- DNAPrint(TM) genomics, Inc.
(OTC Bulletin Board: DNAP)(DNAPrint(TM) or the "Company") today introduced a
new version of its popular ANCESTRYbyDNA(TM) 2.0 test for the genetic
determination of BioGeographical Ancestry (BGA) admixture.
The new test, "ANCESTRYbyDNA(TM) 2.5" provides increased power and
enhanced sensitivity for genealogists because it is powered by 175 rather than
71 Ancestry Informative Markers (AIMs). The test is an augmented version of
ANCESTRYbyDNA(TM) 2.0; 104 new AIMs were added to the core set of 71 used in
the old test. Like the 2.0 version, ANCESTRYbyDNA(TM) 2.5 provides a
customer's proportional Native American, East Asian, Indo-European, and West
Sub-Saharan African BGA, but the increased number of markers allow for more
sensitive and accurate determinations of low levels of admixture (such as that
which may have been contributed by a single great grandparent). The enhanced
sensitivity and efficiency allowed DNAPrint(TM) to also upgrade the
presentation of results for the 2.5 version.
The human genome has millions of markers, or genetic variations, but only
1-2% of these markers (0.002% of the genome) are ancestry informative.
Because the AIMs measured by the test are among the genomes best, and due to
the enhanced coverage of 8 AIMs per average chromosome, ANCESTRYbyDNA(TM) 2.5
represents the most powerful test of its kind ever developed. The new test
sells for $219 per test. Customers who purchased the 2.0 version will receive
an upgrade to 2.5 at a reduced rate of $158.
The new test has been added to the www.ancestrybydna.com website. The
Company is typing samples from discrete populations, such as groups of
individuals who identify with a single ethnic or tribal group. The new
website provides data from simulations that address the accuracy and precision
of the ANCESTRYbyDNA(TM) tests. New data will be added to the website
continuously as it is produced, allowing customers an empirical frame of
reference for interpreting their results.

About DNAPrint(TM) genomics, Inc.
DNAPrint(TM) genomics, Inc., ("DNAPrint(TM)" or the "Company"), is a
genomics science company focused on the sale of proprietary genetic testing
products and services. The Company's core technologies for efficiently
targeting single nucleotide polymorphisms ("SNPs") enable it to provide
predictive genetic tests at a significant cost advantage over its competitors.
The Company has identified and patented the maps of certain SNPs with wide
commercial applications called Ancestry Informative Markers ("AIMS"). The
Company believes that AIMs are the key for unlocking the relationship between
common variants and common anthropometric, disease and drug response traits.
Effectively mapping disease and drug response sequences could lead to the
development of clinical classifiers for improving drug development,
personalizing drug use and empowering forensics investigations. The Company's
patented AIMs are integral to the Company's strategy of offering DNA tests
that provide valuable predictive results, including a person's physical
characteristics, Biogeographical Ancestry ("BGA"), and predisposition to
respond to certain pharmaceutical drugs. The Company's tests target four
distinct markets -- forensics, consumer, pharmacogenomics (predicting drug
response) and outsourced screening services. The Company is traded on the
Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information
about the company, please visit www.dnaprint.com.

All statements in this press release that are not historical are forward-
looking statements within the meaning of Section 21E of the Securities
Exchange Act as amended. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from those
projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost and
pricing of DNAPrint's(TM) products, dependence on collaborations and partners,
regulatory approvals, competition, intellectual property of others, and patent
protection and litigation. DNAPrint(TM) genomics, Inc. expressly disclaims any
obligation or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's(TM) expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.

Media and Press Contacts
Richard Gabriel
DNAPrint(TM) genomics, Inc.
CEO/President
[phone]

SOURCE DNAPrint(TM) genomics, Inc.
-0- 01/27/2004
/CONTACT: Richard Gabriel, CEO and President, DNAPrint(TM) genomics,
Inc.,
[phone]/
/Web site: http://www.dnaprint.com
http://www.ancestrybydna.com /
(DNAP)

CO: DNAPrint(TM) genomics, Inc.
ST: Florida
IN: MTC OTC
SU: PDT
*** end of story ***